Your browser doesn't support javascript.
loading
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance.
Ugarte-Gil, Manuel Francisco; Alarcón, Graciela S; Izadi, Zara; Duarte-García, Ali; Reátegui-Sokolova, Cristina; Clarke, Ann Elaine; Wise, Leanna; Pons-Estel, Guillermo J; Santos, Maria Jose; Bernatsky, Sasha; Ribeiro, Sandra Lúcia Euzébio; Al Emadi, Samar; Sparks, Jeffrey A; Hsu, Tiffany Y-T; Patel, Naomi J; Gilbert, Emily L; Valenzuela-Almada, Maria O; Jönsen, Andreas; Landolfi, Gianpiero; Fredi, Micaela; Goulenok, Tiphaine; Devaux, Mathilde; Mariette, Xavier; Queyrel, Viviane; Romão, Vasco C; Sequeira, Graca; Hasseli, Rebecca; Hoyer, Bimba; Voll, Reinhard E; Specker, Christof; Baez, Roberto; Castro-Coello, Vanessa; Maldonado Ficco, Hernan; Reis Neto, Edgard Torres; Ferreira, Gilda Aparecida Aparecida; Monticielo, Odirlei Andre André; Sirotich, Emily; Liew, Jean; Hausmann, Jonathan; Sufka, Paul; Grainger, Rebecca; Bhana, Suleman; Costello, Wendy; Wallace, Zachary S; Jacobsohn, Lindsay; Taylor, Tiffany; Ja, Clairissa; Strangfeld, Anja; Mateus, Elsa F; Hyrich, Kimme L.
Afiliação
  • Ugarte-Gil MF; Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Cientifica del Sur, Lima, Peru mugarte@cientifica.edu.pe.
  • Alarcón GS; Rheumatology Department, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.
  • Izadi Z; Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Duarte-García A; School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.
  • Reátegui-Sokolova C; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
  • Clarke AE; Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
  • Wise L; Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
  • Pons-Estel GJ; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.
  • Santos MJ; Rheumatology Department, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.
  • Bernatsky S; Unidad de Investigación Para La Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, Lima Peru.
  • Ribeiro SLE; Division of Rheumatology Department of Medicine. Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Al Emadi S; Department of Internal Medicine, Division of Rheumatology, University of Southern California, Los Angeles, California, USA.
  • Sparks JA; Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina.
  • Hsu TY; Research Unit, Argentine Society of Rheumatology, Buenos Aires, Argentina.
  • Patel NJ; Rheumatology, Hospital Garcia de Orta, Almada, Portugal.
  • Gilbert EL; Rheumatology Research Unit. Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
  • Valenzuela-Almada MO; Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, Québec, Canada.
  • Jönsen A; Faculdade de Medicina, Universidade Federal do Amazonas, UFAM, Manaos, Amazonas, Brazil.
  • Landolfi G; Rheumatology Department, Hamad Medical Corp, Doha, Qatar.
  • Fredi M; Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Goulenok T; Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Devaux M; Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital. Harvard Medical School, Boston, Massachusetts, USA.
  • Mariette X; Division of Rheumatology, Mayo Clinic, Jacksonville, Florida, USA.
  • Queyrel V; Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
  • Romão VC; Lund University, Lund, Sweden.
  • Sequeira G; Epidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy.
  • Hasseli R; Rheumatology and Clinical Immunology, ASST Spedali Civili, Brescia, Italy.
  • Hoyer B; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
  • Voll RE; Internal Medicine Department, Bichat Claude Bernard Hospital, APHP, Paris, France.
  • Specker C; Université de Paris, Paris, France.
  • Baez R; Internal Medicine Department, Poissy Saint-Germain-en-Laye Hospital, Poissy, France.
  • Castro-Coello V; Department of Rheumatology, Université Paris-Saclay, Assistance Publique - Hôpitaux de Paris, Le Kremlin Bicêtre, France.
  • Maldonado Ficco H; Department of Rheumatology, Pasteur 2 Hospital, University of Nice -Sophia- Antipolis, Nice, France.
  • Reis Neto ET; Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Ferreira GAA; Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.
  • Monticielo OAA; Centro Hospitalar Universitário do Algarve, Unidade de Faro, Faro, Portugal.
  • Sirotich E; Department of Rheumatology and Clinical Immunology. Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany.
  • Liew J; Department of Rheumatology and Clinical Immunology, Clinic for Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Hausmann J; Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
  • Sufka P; Department of Rheumatology and Clinical Immunology, Kliniken Essen-Mitte, Essen, Germany.
  • Grainger R; Hospital Francisco Lopez Lima, General Roca, Argentina.
  • Bhana S; Sanatorio Güemes, Buenos Aires, Argentina.
  • Costello W; Hospital San Antonio de Padua, Rio Cuarto, Argentina.
  • Wallace ZS; Hospital São Paulo, Universidade Federal de Sao Paulo, Sao Paulo, Brazil.
  • Jacobsohn L; Hospital das Clínicas, Belo Horizonte, Brazil.
  • Taylor T; Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
  • Ja C; Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
  • Strangfeld A; Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
  • Mateus EF; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
  • Hyrich KL; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada.
Ann Rheum Dis ; 81(7): 970-978, 2022 07.
Article em En | MEDLINE | ID: mdl-35172961
AIM: To determine characteristics associated with more severe outcomes in a global registry of people with systemic lupus erythematosus (SLE) and COVID-19. METHODS: People with SLE and COVID-19 reported in the COVID-19 Global Rheumatology Alliance registry from March 2020 to June 2021 were included. The ordinal outcome was defined as: (1) not hospitalised, (2) hospitalised with no oxygenation, (3) hospitalised with any ventilation or oxygenation and (4) death. A multivariable ordinal logistic regression model was constructed to assess the relationship between COVID-19 severity and demographic characteristics, comorbidities, medications and disease activity. RESULTS: A total of 1606 people with SLE were included. In the multivariable model, older age (OR 1.03, 95% CI 1.02 to 1.04), male sex (1.50, 1.01 to 2.23), prednisone dose (1-5 mg/day 1.86, 1.20 to 2.66, 6-9 mg/day 2.47, 1.24 to 4.86 and ≥10 mg/day 1.95, 1.27 to 2.99), no current treatment (1.80, 1.17 to 2.75), comorbidities (eg, kidney disease 3.51, 2.42 to 5.09, cardiovascular disease/hypertension 1.69, 1.25 to 2.29) and moderate or high SLE disease activity (vs remission; 1.61, 1.02 to 2.54 and 3.94, 2.11 to 7.34, respectively) were associated with more severe outcomes. In age-adjusted and sex-adjusted models, mycophenolate, rituximab and cyclophosphamide were associated with worse outcomes compared with hydroxychloroquine; outcomes were more favourable with methotrexate and belimumab. CONCLUSIONS: More severe COVID-19 outcomes in individuals with SLE are largely driven by demographic factors, comorbidities and untreated or active SLE. Patients using glucocorticoids also experienced more severe outcomes.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Reumatologia / COVID-19 / Lúpus Eritematoso Sistêmico Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Ann Rheum Dis Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Peru País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Reumatologia / COVID-19 / Lúpus Eritematoso Sistêmico Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Ann Rheum Dis Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Peru País de publicação: Reino Unido